TargetMol

NKG2D/CD314 Protein, Human, Recombinant (hFc & Flag), FITC-Labeled

Product Code:
 
TAR-TMPK-00107
Product Group:
 
Recombinant Proteins
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1

Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TMPK-00107-100ug100ugEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TMPK-00107-1mg1mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TMPK-00107-500ug500ugEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Bioactivity:
NKG2D is a type II transmembrane glycoprotein having an extracellular lectin-like domain. This domain lacks the recognizable calcium-binding sites found in true C-type lectins and binds protein rather than carbohydrate ligands. Human NKG2D is expressed on CD8 alpha beta T cells, gamma δ T cells, NK cells and NKT cells. NKG2D/CD314 Protein, Human, Recombinant (hFc & Flag), FITC-Labeled is expressed in HEK293 mammalian cells with N-hFc-Flag tag. The predicted molecular weight is 43.4 kDa and the accession number is P26718.
Molecular Weight:
43.4 kDa (predicted). Due to glycosylation, the protein migrates to 50-70 kDa based on Tris-Bis PAGE result.
Purity:
98%

References

1.Spear P, et al. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors[J]. Immunology and Cell Biology, 2013, 91(6):435-440.